跳至主要内容
临床试验/JPRN-jRCT2080221094
JPRN-jRCT2080221094未知3 期

A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler 0.4 mg and Salbutamol pMDI 200mcg - a Single Blind, Single Dose, Randomized, Crossover, Phase 3 Study in Japanese Adult Asthma Patients

AstraZeneca0 个研究点开始时间: 2010年5月12日最近更新:
适应症

试验速览

阶段
3 期
发起方
AstraZeneca

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 16age old 至 ot applicable(—)
性别
All

入选标准

  • On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during the 4 weeks prior to Visit 2
  • - FEV1 of at least 50 % of predicted normal value pre-bronchodilator
  • - Reversible airway obstruction according to reversibility test performed at Visit 2, defined as an increase in FEV1 12% or more relative baseline at 15-30 minutes after inhalation of in total 400mcg salbutamol

排除标准

  • - Treatment with oral, parenteral or rectal GCS within 4 weeks or depot parenteral GCS within 3 months prior to Visit 2.
  • - Change in prescribed asthma medication due to exacerbation of asthma within 4 weeks prior to Visit 2 or being hospitalized due to exacerbation of asthma within 8 weeks prior to Visit 2.

研究者

发起方
AstraZeneca

相似试验

A Study to Investigate the Relative Efficacy of... | 临床试验